SCHEMBL21247176

SCHEMBL21247176

Cc1sc(NC(=O)c2ccc(NCC3CCOCC3)cc2)c(C(=O)O)c1C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRIN2C Q14957 2/20 0.55
▸ ALDH1A1 P00352 8/20 0.47
▸ MAPT P10636 5/20 0.47
▸ HPGD P15428 5/20 0.47
▸ LMNA P02545 2/20 0.47
▸ PLA2G1B P04054 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ ATG4B Q9Y4P1 1/20 0.47
▸ ABCC1 P33527 2/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ KDM4E B2RXH2 2/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ CYP1A2 P05177 3/20 0.42
▸ CYP2C9 P11712 2/20 0.42
▸ CYP2C19 P33261 2/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ NAMPT P43490 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21247243 0.81 MAPT (0.60) GRIN2CALDH1A1MAPTHPGDLMNA
SCHEMBL21247406 0.81 KMT2A (0.61) GRIN2CALDH1A1MAPTHPGDLMNA
SCHEMBL21247160 0.81 PTPN1 (0.51) GRIN2CALDH1A1MAPTHPGDLMNA
SCHEMBL21247284 0.80 RAB7A (0.54) GRIN2CALDH1A1MAPTHPGDLMNA
SCHEMBL21247129 0.80 CFTR (0.47) ALDH1A1MAPTHPGDLMNAKDM4E
SCHEMBL21259098 0.79 GRIN2C (0.44) GRIN2CALDH1A1MAPTHPGDLMNA
SCHEMBL21259095 0.79 MEN1 (0.41) GRIN2CALDH1A1MAPTHPGDLMNA
SCHEMBL21253167 0.79 MEN1 (0.60) GRIN2CALDH1A1MAPTHPGDLMNA
SCHEMBL21253035 0.78 CCNK (0.39) GRIN2CALDH1A1MAPTHPGDLMNA
SCHEMBL21247338 0.77 MEN1 (0.39) GRIN2CALDH1A1MAPTHPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3749649-A1 NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO Pharma (FR) 2020-12-16 — — EP claimed
US-20200369655-A1 NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2020-11-26 — — US claimed
WO-2019154953-A1 NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2019-08-15 — — WO claimed
US-11840527-B2 Non-fused thiophene derivatives and their uses ENYO PHARMA (FR) 2023-12-12 — — US disclosed
US-11840527-B2 Non-fused thiophene derivatives and their uses ENYO PHARMA (FR) 2023-12-12 — — US disclosed
US-11840527-B2 Non-fused thiophene derivatives and their uses ENYO PHARMA (FR) 2023-12-12 — — US disclosed
EP-3749649-A1 NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO Pharma (FR) 2020-12-16 — — EP disclosed
US-20200369655-A1 NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2020-11-26 — — US disclosed
US-20200369655-A1 NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2020-11-26 — — US disclosed
WO-2019154953-A1 NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2019-08-15 — — WO disclosed
WO-2019154953-A1 NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2019-08-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200369655-A1 NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES FTH1, SLC40A1, FECH GRIN2C 3459/4885ALDH1A1 1977/4885MAPT 2844/4885
US-11840527-B2 Non-fused thiophene derivatives and their uses FTH1, SLC40A1, FECH GRIN2C 3459/4885ALDH1A1 1977/4885MAPT 2844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback